Peterson Capital Hosts Canada Growth Conference in Ireland

Peterson Capital Hosts Canada Growth Conference in Ireland

Seven of Canada's fastest growing public companies will be gathering outside of Dublin today as they kick off the third Canada Growth Conference hosted by Edmonton-based capital markets advisory firm Peterson Capital.

More than fifty public company CEOs, Investment Advisors, fund managers and family offices will meet at the Powerscourt Hotel Resort from Thursday evening, September 25 th to Saturday noon, September 27 th for presentations, informal receptions, meetings and social gatherings designed to highlight the opportunities that each of the public companies offers to potential investors.

"We've held two conferences with the exact same format as this one in Montreal last May and in France in 2022," said Greg Stumph , Peterson Capital's President & COO, "and the feedback from everyone was extremely positive.

"We have an extremely impressive group of attendees here again – both from our clients and the investor guests - and we're encouraging them to spend time getting to know each other and establish connections that will last beyond the conference. Aside from the presentations, we're also having fun on Saturday with our seven CEOs by putting each of them through a ‘Bear Pit' session and really getting to learn more about each of them. That was extremely popular in Montreal and we're expecting it to be a highlight again here this weekend."

  • The seven companies presenting are Peterson Capital clients Eupraxia Pharmaceuticals (NASDAQ:EPRX) (TSX:EPRX) , Logan Energy (LGN.V), Wesdome Gold Mines Ltd. (TSX:WDO, OTCQX:WDOFF) , Colonial Coal International Corp. (TSX-V: CAD), Volatus Aerospace Inc. (TSXV:FLT) (OTCQX:TAKOF) (Frankfurt: ABB), PowerWood Canada and Hypercharge Networks Corp. (TSXV: HC) (OTCQB: HCNWF) (FSE: PB7) .

Conference attendees will vote on Saturday at noon on the company that they feel was the top growth story of the conference. The winner will take home the Canada Growth Cup, which was awarded to Eupraxia Pharmaceuticals in Montreal last May and to Volatus Aerospace at the inaugural Canada Growth Conference in the south of France in 2022.

"Interest in Canadian growth stories has never been higher," said Peterson Capital founder Rick Peterson, "and this event is a testament to that. Attendance numbers are the highest we've seen in our three conferences. The Embassy of Canada to Ireland based in Dublin will be there and our keynote speaker at lunch on Friday will be Richard McGrath, Executive Director and Head of Investment of AGF International Advisors in Dublin."

About Peterson Capital :

Peterson Capital is a capital markets advisory firm founded in 2003 with its head office is in Edmonton and regional offices from coast-to-coast across Canada as well as into Europe and the UK. The company provides introductory services to a network of Investment Advisors, fund managers and family office CEOs with access to more than $15 billion in discretionary investment capital.

For more information, please contact Greg Stumph at greg@petersoncapital.ca .


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

EPRX:CA
The Conversation (0)
Eupraxia Pharmaceuticals Reports Fourth Quarter and 2022 Financial Results

Eupraxia Pharmaceuticals Reports Fourth Quarter and 2022 Financial Results

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its audited financial results (prepared in accordance with International Financial Reporting Standards or... Keep Reading...
Eupraxia Pharmaceuticals Completes Patient Enrollment for its Phase 2 Trial in Knee Osteoarthritis

Eupraxia Pharmaceuticals Completes Patient Enrollment for its Phase 2 Trial in Knee Osteoarthritis

- Company remains on track for Phase 2 data readout in Q2 2023 - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has completed enrollment,... Keep Reading...
Eupraxia Pharmaceuticals Reports Third Quarter 2022 Financial Results

Eupraxia Pharmaceuticals Reports Third Quarter 2022 Financial Results

Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced its unaudited financial results (prepared in accordance with International Financial Reporting Standards... Keep Reading...
Eupraxia Pharmaceuticals Appoints Chief Business Officer

Eupraxia Pharmaceuticals Appoints Chief Business Officer

--Industry Veteran Paul Brennan Appointed Effective Nov 1 st -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced that it has appointed Paul Brennan to the... Keep Reading...
Eupraxia Pharmaceuticals Initiates Phase 2 Study in Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Initiates Phase 2 Study in Eosinophilic Esophagitis

-Represents second Phase 2 program for EP-104IAR, with initial data readout anticipated in H1, 2023- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today announced the... Keep Reading...
Imagion Biosystems

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, is pleased to provide shareholders with a progress update regarding the Company’s business and... Keep Reading...
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare. But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no... Keep Reading...
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This... Keep Reading...
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access... Keep Reading...
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will... Keep Reading...
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Latest Press Releases

Related News